Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC29A1 | Q99808 | 2/20 | 0.54 |
| ▸ | SLC28A1 | O00337 | 1/20 | 0.54 |
| ▸ | SLC28A2 | O43868 | 1/20 | 0.54 |
| ▸ | SLC28A3 | Q9HAS3 | 1/20 | 0.54 |
| ▸ | P2RY2 | P41231 | 6/20 | 0.47 |
| ▸ | P2RY4 | P51582 | 3/20 | 0.47 |
| ▸ | POLA1 | P09884 | 1/20 | 0.42 |
| ▸ | P2RY14 | Q15391 | 3/20 | 0.40 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.39 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.39 |
| ▸ | P2RY6 | Q15077 | 3/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15075226 | 0.90 | SLC29A1 (0.56) | SLC29A1SLC28A1SLC28A2SLC28A3P2RY2 | |
| SCHEMBL14405971 | 0.90 | SLC29A1 (0.56) | SLC29A1SLC28A1SLC28A2SLC28A3P2RY2 | |
| SCHEMBL3969711 | 0.89 | SLC29A1 (0.60) | SLC29A1SLC28A1SLC28A2SLC28A3P2RY2 | |
| SCHEMBL6271158 | 0.88 | SLC29A1 (0.59) | SLC29A1SLC28A1SLC28A2SLC28A3P2RY2 | |
| Succinic Acid SCHEMBL992636 | 0.86 | SLC28A1 (0.45) | SLC29A1SLC28A1SLC28A2SLC28A3P2RY2 | |
| SCHEMBL19352334 | 0.85 | SLC29A1 (0.56) | SLC29A1SLC28A1SLC28A2SLC28A3P2RY2 | |
| SCHEMBL20830177 | 0.85 | SLC29A1 (0.56) | SLC29A1SLC28A1SLC28A2SLC28A3P2RY2 | |
| SCHEMBL5420938 | 0.85 | SLC29A1 (0.56) | SLC29A1SLC28A1SLC28A2SLC28A3P2RY2 | |
| SCHEMBL19352333 | 0.85 | SLC29A1 (0.56) | SLC29A1SLC28A1SLC28A2SLC28A3P2RY2 | |
| SCHEMBL19352335 | 0.85 | SLC29A1 (0.56) | SLC29A1SLC28A1SLC28A2SLC28A3P2RY2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7071311-B2 | Antibodies having specificity for 2′-C-allyl nucleic acids | SIRNA THERAPEUTICS, INC. (US) | 2006-07-04 | — | — | US | disclosed |
| US-20050042632-A1 | Antibodies having specificity for nucleic acids | SIRNA THERAPEUTICS, INC. (US) | 2005-02-24 | — | — | US | disclosed |
| US-20030228590-A1 | Antibodies having specificity for nucleic acids | SIRNA THERAPEUTICS, INC. | 2003-12-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050042632-A1 | Antibodies having specificity for nucleic acids | SNRPE, RNASE1, FCGR2A | SLC29A1 58/4885SLC28A1 507/4885SLC28A2 632/4885 |
| US-20030228590-A1 | Antibodies having specificity for nucleic acids | DUT, NSUN3, DNASE1L3 | SLC29A1 19/4885SLC28A1 320/4885SLC28A2 328/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.